The DOI matches its Crossref record; 158 of the 159 references it cites were found in a registry or an index.
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Abstract
Tissue hypoxia results from an inadequate supply of oxygen (O(2)) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for hypoxia in solid tumors. Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions. Tumor hypoxia appears to be strongly associated with tumor propagation, malignant progression, and resistance to therapy, and it has thus become a central issue in tumor physiology and cancer treatment. Biochemists and clinicians (as well as physiologists) define hypoxia differently; biochemists define it as O(2)-limited electron transport, and physiologists and clinicians define it as a state of reduced O(2) availability or decreased O(2) partial pressure that restricts or even abolishes functions of organs, tissues, or cells. Because malignant tumors no longer execute functions necessary for homeostasis (such as the production of adequate amounts of adenosine triphosphate), the physiology-based definitions of the term "hypoxia" are not necessarily valid for malignant tumors. Instead, alternative definitions based on clinical, biologic, and molecular effects that are observed at O(2) partial pressures below a critical level have to be applied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
(1989) · PubMed · Cited by 3,343
Self-citationHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727
Self-citation
Research works printed but not linked: 35
- Brown, 1998, Cancer Research, 58, 1408
- Hockel, 1996, Cancer Research, 56, 4509
- Brizel, 1996, Cancer Research, 56, 941
- Walenta, 2000, Cancer Research, 60, 916
- Hockel, 1999, Cancer Research, 59, 4525
- Kim, 1997, Cancer Research, 57, 4200
- Anthoney, 1996, Cancer Research, 56, 1374
- Vaupel, 1989, Cancer Research, 49, 6449
- Vaupel, 1987, Cancer Research, 47, 3496
- Kallinowski, 1989, Cancer Research, 49, 3759
- 1973, Advances in experimental medicine and biology, 37, 277
- Vaupel, 1991, Cancer Research, 51, 3316
- Hockel, 1991, Cancer Research, 51, 6098
- Wilson, 1992, Cancer Research, 52, 3988
- 1996, BRITISH JOURNAL OF CANCER, 74, S226
- Valk, 1992, Journal of Nuclear Medicine, 33, 2133
- Groshar, 1993, Journal of Nuclear Medicine, 34, 885
- Lord, 1993, Cancer Research, 53, 5721
- Evans, 1996, Cancer Research, 56, 405
- Riva, 1998, Anticancer Research, 18, 4729
- Prehn, 1991, Cancer Research, 51, 2
- Ausserer, 1994, Molecular and Cellular Biology, 14, 5032, 10.1128/mcb.14.8.5032 · DOI
- Hartmann, 1999, Cancer Research, 59, 1578
- Koong, 1994, Cancer Research, 54, 1425
- Henderson, 1987, Cancer Research, 47, 3110
- Mitchell, 1985, Cancer Research, 45, 2008
- Reynolds, 1996, Cancer Research, 56, 5754
- Stoler, 1992, Cancer Research, 52, 4372
- Russo, 1995, Cancer Research, 55, 1122
- Teicher, 1990, Cancer Research, 50, 3339
- Teicher, 1981, Cancer Research, 41, 73
- Moan, 1985, Cancer Research, 45, 1608
- 1981, Bibliotheca anatomica, 20, 628
- 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 46, S107
- 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 48, S162
Cited by
Sorted by citations
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
“A large body of data has indicated that hypoxic cancer cells are more likely to be resistant to radiation and chemotherapy, and have increased potential for invasion, metastasis and patient mortalit”
BackgroundOxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
“tumors is associated with increased metastasis and poor survival of patients with several forms of squamous tumor [232,233].”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
“Direct evidence of hypoxia in human cancers has been shown most convincingly by the pioneering work of Peter Vaupel and colleagues, who studied the tumour oxygen supply using oxygen electrode”
BackgroundReactive oxygen species in cancer
Liou, G., & Störz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,528
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Self-citationHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
“Such a supply-demand mismatch can occur in physiologic conditions such as the exercising muscle, in the pathologic condition such as the ischemic heart, or in the tumor microenvironment (Hockel and Vaupel, 2001; Semenza, 2004).”
BackgroundReactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. S. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,121
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
“Tumour cells respond to these conditions, and adapt their metabolism to adjust the O 2 demand to meet the limited suppl”
BackgroundBingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
“The presence of multiple areas of hypoxia (pathologically low oxygen tension) is a hallmark feature of many types of human tumour [98].”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Lü, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.75 · Cited by 1,448
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedTumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,294
“Several chemotherapeutic drugs are also less active in the acidic microenvironment associated with hypoxia (reviewed in Hockel and Vaupel, 2001; Minchinton and Tannock, 2006).”
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
“Increased metastases, enhanced tumor progression, and decreased patient survival have been associated with primary tumors that contain large numbers of poorly oxygenated (hypoxic) tumor cells (Cairns et al., 2003; Hockel and Vaupel, 2001; Pouyssegur et al., 2006).”
BackgroundDiffuse optics for tissue monitoring and tomography
Durduran, T., Choe, R., Baker, W. B., & Yodh, A. G. (2010) · Reports on Progress in Physics · doi:10.1088/0034-4885/73/7/076701 · Cited by 1,168
“[351–353].”
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
A dual-emissive-materials design concept enables tumour hypoxia imaging
Zhang, G., Palmer, G. M., Dewhirst, M. W., & Fraser, C. L. (2009) · Nature Materials · doi:10.1038/nmat2509 · Cited by 1,154
HIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
van Straten, D., Mashayekhi, V., de Bruijn, H., Oliveira, S., & Robinson, D. J. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,042
“These low oxygen areas are already present pre-PDT [316] or emerge due to PDT oxygen consumption or vascular collapse [54].”
BackgroundReactive oxygen species in tumor progression
Peter, S. F. (2005) · Frontiers in bioscience · doi:10.2741/1667 · Cited by 972
“This adaptation of tumor cells to hypoxia contributes to the malignant phenotype and to aggressive tumor progression (27), and low oxygen tension in tumors is associated with increased metastasis and poor survival of patients in several squamous tumors (28, 29).”
BackgroundRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
“Associations between microenvironmental hypoxia, activation of hypoxia pathways, and aggressively malignant phenotypes are observed across a range of cancers, focusing attention on molecular dissection of these pathways and how they contribute to tumor biology (8, 9).”
BackgroundTumor microenvironmental physiology and its implications for radiation oncology
Vaupel, P. W. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.008 · Cited by 966
Self-citationCheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941
Rozpędek‐Kamińska, W., Pytel, D., Mucha, B., Leszczynska, H., Diehl, J. A., & Majsterek, I. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160523143937 · Cited by 894
“The uncontrolled growth of tumor cells forming an enlarging mass causes the distance between existing blood vessels to increase and creates areas of acute and chronic hypoxia [27].”
BackgroundLu, H., Forbes, R. A., & Verma, A. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202487200 · Cited by 832
The Role of Hypoxia-Induced Factors in Tumor Progression
Vaupel, P. W. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-10 · Cited by 851
“It has also been suggested that hypoxia exerts a strong selection pressure on malignant cells [5, 6 , 51, 52].”
BackgroundInfluentialSelf-citationThe role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response
Vaupel, P., & Harrison, L. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-4 · Cited by 761
“Evidence from recent studies suggests that sustained (>6-8 hours) or fluctuating hypoxic stress (pO2 ≤7 mmHg) can lead to alterations (stimulation or inhibition) of gene expression, as well as posttranscriptional and posttranslational modulations that result in changes in the tumor cell proteome (Fig. 6) [ 9-11 , 16].”
BackgroundInfluentialSelf-citationShining carbon dots: Synthesis and biomedical and optoelectronic applications
Yuan, F., Li, S., Fan, Z., Meng, X., Fan, L., & Yang, S. (2016) · Nano Today · doi:10.1016/j.nantod.2016.08.006 · Cited by 755
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
Holmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, Å., Gradin, K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.026 · Cited by 735
ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth
Bi, M., Naczki, C., Koritzinsky, M., Fels, D. R., Blais, J. D., Hu, N., Harding, H. P., Novoa, I., Varia, M. A., Raleigh, J. A., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600777 · Cited by 756
“The development of fluctuating hypoxic and anoxic regions in tumors has profound consequences for malignant progres- sion, response to therapy and overall patient survival (Hockel and Vaupel, 2001).”
BackgroundDetection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
“In this discussion of hypoxic thresholds, it is important to note that, for any particular functional parameter, a sharp threshold between “hy-poxia” ( i.e. , more hypoxic tumors) and “normoxia” ( i.e. , less hypoxic tumors) does not exist and should not be expected (51).”
InfluentialSelf-citationDelivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“%) is estimated to represent a critical PO2 since lower PO2 values are associated with adverse effects caused by reduced O2 consumption (Hockel & Vaupel, 2001).”
BackgroundPastoreková, S., Parkkila, S., Pastorek, J., & Supuran, C. T. (2004) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360410001689540 · Cited by 662
Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance
Mallidi, S., Luke, G. P., & Emelianov, S. (2011) · Trends in biotechnology · doi:10.1016/j.tibtech.2011.01.006 · Cited by 646
“Hypoxia is often linked to malignancy and resistance to therapy [32].”
BackgroundTargeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 645
“tween tumor cell proliferation, which is faster than the rate of blood vessel formation, thereby leading to a compromised tumor blood supply [217].”
BackgroundTatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 626
“There appears to be a vicious circle (Hockel & Vaupel 2001a, Hockel & Vaupel 2001b) in which hypoxia-induced changes promote malignant progression and increased aggressiveness, leading to tumor propagation and further tumor hypoxia.”
BackgroundImaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 628
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
“Tumor hypoxia correlated with poor outcome even when surgery was the only treatment and is now considered as a prognostic factor for overall tumor aggressiveness and resistance to therapy [Hockel and Vaupel, 2001].”
BackgroundGraham, K., & Unger, E. C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s140462 · Cited by 594
“tissue.(15) Profound hypoxia promotes changes in the proteome and genome.”
BackgroundTreatment Resistance of Solid Tumors
Vaupel, P. W., Thews, O., & Hoeckel, M. (2001) · Medical Oncology · doi:10.1385/mo:18:4:243 · Cited by 571
“Other consequences of hypoxia-induced malignant progression are an increased locoregional spread and enhanced metastasis ( 4 ,87).”
BackgroundInfluentialSelf-citationTumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Nonlinear modelling of cancer: bridging the gap between cells and tumours
Lowengrub, J. S., Frieboes, H. B., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S. M., & Vittorio Cristini, C. (2009) · Nonlinearity · doi:10.1088/0951-7715/23/1/r01 · Cited by 565
“It is also supposed that the pressure jump across the necrotic interface is zero, which reflects the low cell–cell adhesion in the perinecrotic region and the increased cellular mobility observed in hypoxic cells [75,99,265,423,424,454].”
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 580
Role of iron in carcinogenesis: cancer as a ferrotoxic disease
Toyokuni, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01001.x · Cited by 552
Regulation of tumor pH and the role of carbonic anhydrase 9
Swietach, P., Vaughan-Jones, R. D., & Harris, A. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9064-0 · Cited by 539
“after the onset of angiogenesis, O2 delivery may remain inadequate because the vasculature is often abnormal and heterogeneous [35].”
BackgroundTargeted photoredox catalysis in cancer cells
Huang, H., Banerjee, S., Qiu, K., Zhang, P., Blacque, O., Malcomson, T., Paterson, M. J., Clarkson, G. J., Staniforth, M. J., Stavros, V. G., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0328-4 · Cited by 561
Cancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
“byproduct of radiotherapy, would normally induce DNA damage in tumor cells (20).”
BackgroundSkeletal PET with 18 F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A. A., & Treves, S. T. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 516
Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia
Kaidi, A., Williams, A. C., & Paraskeva, C. (2007) · Nature Cell Biology · doi:10.1038/ncb1534 · Cited by 529
“However, in the course of tumorigenesis, tumour expansion is constrained by alterations in its microenvironment, typically caused by the inadequacy of the local vasculature to supply sufficient oxygen and nutrients to the rapidly growing tumour, resulting in hypoxi”
BackgroundTumor hypoxia and malignant progression
Vaupel, P., Mayer, A., & Höckel, M. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)81023-1 · Cited by 496
Self-citationBos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500
Role of hypoxia in the hallmarks of human cancer
Ruan, K., Song, G., & Ouyang, G. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22214 · Cited by 493
“The frequency of point mutations in tumorigenic cells cultured under severe hypoxic treatment is 3.4-fold higher than that observed in normally oxygenated cells [Hockel and Vaupel, 2001].”
BackgroundInfluentialOxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy
Vaupel, P. W., Kelleher, D. K., & ]ckel, M. H. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90210-6 · Cited by 481
Self-citationYC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E., Chun, Y., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 479
The emerging role of photoacoustic imaging in clinical oncology
Lin, L., & Wang, L. V. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00615-3 · Cited by 497
Li, W., Zhou, C., Yu, L., Hou, Z., Liu, H., Kong, L.-H., Xu, Y., He, J., Jin, L., Ou, Q., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2249762 · Cited by 502
Cancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
The linear quadratic model: usage, interpretation and challenges
McMahon, S. J. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aaf26a · Cited by 444
Src signaling in cancer invasion
Guarino, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22011 · Cited by 427
“Furthermore, hypoxia—a common characteristic of the tumor microenvironment (Höckel and Vaupel, 2001; Pennacchietti et al., 2003), can favor invasive growth and malignant progression by stimulating the Src/STAT3/VEGF pathway which then promotes angiogenesis, a step necessary for the growth of both…”
BackgroundSTAT3 is a potential modulator of HIF‐1‐mediated VEGF expression in human renal carcinoma cells
Jung, J. E., Lee, H. S., Cho, I., Chung, D. H., Yoon, S., Yang, Y. M., Lee, S. E., Choi, S., Park, J., Ye, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3099fje · Cited by 431
Walsh, J. C., Lebedev, A. Y., Aten, E., Madsen, K. S., Marciano, L., & Kolb, H. C. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 432
“This survival mechanism is common among hypoxic tumors, resulting in a twofold increase in glucose uptake (determined in vitro) (29), elevated tissue acidity (44), and an evolutionary selection for a progressively more malignant phenotype (102, 122).”
Biomedical Applications of Photoacoustic Imaging with Exogenous Contrast Agents
Luke, G. P., Yeager, D., & Emelianov, S. (2011) · Annals of Biomedical Engineering · doi:10.1007/s10439-011-0449-4 · Cited by 417
Jin, C. S., Lovell, J. F., Chen, J., & Zheng, G. (2013) · ACS Nano · doi:10.1021/nn3058642 · Cited by 414
“tentiate tumor hypoxia, impeding therapeutic outcomes.(10,12,18,19) Thus, an oxygen-indepen-”
Cao, X., Ding, L., Xie, Z., Yang, Y., Whiteman, M., Moore, P. K., & Bian, J. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7058 · Cited by 412
Targeting tumor-associated carbonic anhydrase IX in cancer therapy
Thiry, A., Dogné, J., Masereel, B., & Supuran, C. T. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.002 · Cited by 396
“In tumors, hypoxia stems from an inadequate supply of oxygen, which is primarily a pathophysiological consequence of structurally and functionally disturbed microcirculation and the deterioration of O2 diffusion processes [ 7 ].”
BackgroundInfluentialHypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397
Furuta, E., Pai, S. K., Zhan, R., Bandyopadhyay, S., Watabe, M., Mo, Y., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2489 · Cited by 404
“On the other hand, traditional chemotherapeutic agents commonly used for breast cancer treatment such as cyclophosphamide, carboplatin, and doxorubicin often become ineffective due to chemoresistance, particularly under hypoxic condition ( 52 ).”
BackgroundAngiogenesis Ischemic and Neoplastic Disorders
Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386
Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
Mo, R., & Gu, Z. (2015) · Materials Today · doi:10.1016/j.mattod.2015.11.025 · Cited by 386
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
Meijer, T. W. H., Kaanders, J. H. A. M., Span, P. N., & Bussink, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0858 · Cited by 433
Autophagy: a barrier or an adaptive response to cancer
Ogier‐Denis, É., & Codogno, P. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00004-0 · Cited by 370
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Kaanders, J. H. A. M., Wijffels, K. I. E. M., Marres, H. A. M., Ljungkvist, A. S. E., Pop, L. A. M., van den Hoogen, F. J. A., de Wilde, P. C. M., Bussink, J., Raleigh, J. A., & van der Kogel, A. J. (2002) · PubMed · Cited by 357
Paul, C., Teng, S., & Saunders, P. T. K. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.071779 · Cited by 364
“This can be in response to inadequate blood flow into the tissue or reduced oxygen transport capacity [11].”
BackgroundLi, M.-L., Oh, J., Xie, X., et al. (2008) · Proceedings of the IEEE · doi:10.1109/jproc.2007.913515 · Cited by 352
“Imaging of the oxygenation status of tumors, especially hypoxia, is receiving more and more attention in assessing tumor growth, malignant progression, metastasis, and resistance to various therapiesV including radiotherapy and chemotherapy as well as photodynamic therapy [23]–[ 27 ].”
BackgroundTumor hypoxia: A target for selective cancer therapy
Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 356
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N. G., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 365
Zhang, S., Hosaka, M., Yoshihara, T., Negishi, K., Iida, Y., Tobita, S., & Takeuchi, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3948 · Cited by 351
Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?
Harrison, L. B., & Blackwell, K. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-31 · Cited by 359
“As indicated in Figure 1 and Table 1, hypoxia may also substantially enhance radioresistance by inducing proteomic and genomic changes that lead to increases in the number of tumor cells with diminished apoptotic potential or increased proliferative and metastatic potential, or that lead to increases in the levels of…”
BackgroundResultInfluentialJan, S. L., Amy, C., Cazes, A., Monnot, C., Lamandé, N., Favier, J., Philippe, J., Sibony, M., Gasc, J., Corvol, P. L., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64285-x · Cited by 342
“7 Indeed, HIF-1 (cid:2) regulates many genes, including those for erythropoietin, vascular endothelial growth factor (VEGF), tyrosine hydroxylase, inducible NO synthase (iNOS), and angiopoietin-2.”
BackgroundAirley, R. E., & Mobasheri, A. (2007) · Chemotherapy · doi:10.1159/000104457 · Cited by 342
“For example, the active species of bleomycin depends upon the formation of a DNA-bleomycin-ferrous ion-dioxygen complex that is oxidized in the presence of molecular oxygen [ ,”
BackgroundSignalling hypoxia by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.111 · Cited by 343
Is diabetic retinopathy an inflammatory disease?
Adamis, A. P. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.4.363 · Cited by 343
HIF-1 regulation: not so easy come, easy go
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.002 · Cited by 339
“The physiology of hypoxia Hypoxia is a state of reduced oxygen pressure below a critical threshold, which restricts the function of organs, tissues or cells [ 1 ].”
BackgroundDuan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y. H., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 349
Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions
Padhani, A. R., Koh, D., & Collins, D. J. (2011) · Radiology · doi:10.1148/radiol.11110474 · Cited by 332
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
“microenvironment is not only hypoxic and acidic but also is surrounded by high interstitial pressure, which acts as a pathologic barrier to drug delivery into tumors (Gatenby and Gillies, 2004; Hockel and Vaupel, 2001; Jain, 2005).”
BackgroundStimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 340
“The pathogenesis of tumor hypoxia is well explained by Vaupel et al [74, 75].”
BackgroundMetabolomics in cancer biomarker discovery: Current trends and future perspectives
Armitage, E. G., & Barbas, C. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.08.041 · Cited by 343
Imaging oxygenation of human tumours
Padhani, A. R., Krohn, K. A., Lewis, J. S., & Alber, M. L. (2006) · European Radiology · doi:10.1007/s00330-006-0431-y · Cited by 328
“With these caveats in mind, the critical pO2 tensions below which cellular functions progressively cease or anticancer treatments are impaired are approximately as follows [13]: Effectiveness of immunotherapy becomes impaired (30–35 mmHg); Photodynamic therapy (15–35 mmHg); Cell death on exposure to radiation (25– 30…”
BackgroundHyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy
Gong, H., Chao, Y., Xiang, J., Han, X., Song, G., Feng, L., Liu, J., Yang, G., Chen, Q., & Liu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00068 · Cited by 323
MRI-Guided Diffuse Optical Spectroscopy of Malignant and Benign Breast Lesions
Ntziachristos, V., Yodh, A. G., Schnall, M. D., & Chance, B. (2002) · Neoplasia · doi:10.1038/sj.neo.7900244 · Cited by 321
pH ‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents
Karimi, M., Eslami, M., Sahandi‐Zangabad, P., Mirab, F., Farajisafiloo, N., Shafaei, Z., Ghosh, D., Bozorgomid, M., Dashkhaneh, F., & Hamblin, M. R. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1389 · Cited by 327
Three-dimensional context regulation of metastasis
Erler, J. T., & Weaver, V. M. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9209-8 · Cited by 327
Metadata
- Authors
- Hockel, M., & Vaupel, P.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Vaupel, P.
- ORCID
- Vaupel, P.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-21
- Volume
- 93
- Issue
- 4
- Pages
- 266-276
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2125257427
- Semantic Scholar
- 6c70b98add72efaae8670b5183983be403de59ae
- Cited by
- 2,662
- References
- 159
- Citations by year
- 2026: 46 · 2025: 65 · 2024: 93 · 2023: 134 · 2022: 110 · 2021: 139 · 2020: 149 · 2019: 120 · 2018: 110 · 2017: 148 · 2016: 143 · 2015: 123 · 2014: 114 · 2013: 104 · 2012: 114
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor hypoxia, tissue hypoxia, solid tumors, tumor microcirculation, oxygen partial pressure, tumor progression, treatment resistance, tumor physiology, oxygen diffusion
- MeSH terms
- Animals, Humans, Neoplasms, Oxygen, Predictive Value of Tests, Prognosis, Risk Factors, Cell Hypoxia, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
